GC
VYNE icon

Grace Capital’s VYNE Therapeutics VYNE Stock Holding History

Grace Capital’s Portfolio VYNE Stock Details VYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-250
Closed -$28K – 258
2020
Q4 		$28K Buy
+250
New +$31.4K 0.02% 229
2020
Q3 		– Sell
-500
Closed -$62K – 247
2020
Q2 		$62K Buy
500
+335
+203% +$45.4K 0.05% 175
2020
Q1 		$32K Buy
+165
New +$51.8K 0.03% 155

Other funds holding VYNE

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
HVC
Healthcare Value Capital Woodcliff Lake, New Jersey $50.7M AUM 24.72% 1-Year Est. Return

Grace Capital's VYNE Position: Q1 2021 in Review

Grace Capital sold out of VYNE Therapeutics (VYNE) in Q1 2021, closing a stake of 250 shares — an estimated $28K sold.

Grace Capital first reported a position in VYNE in Q1 2020 and held it in 3 quarters. The position peaked at $62K in Q2 2020. 89 funds tracked by Wall St. Rank hold VYNE as of Q1 2021.

  • Grace Capital reported no remaining VYNE Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Grace Capital sold 250 VYNE Therapeutics shares in Q1 2021, an estimated $28K.
  • Grace Capital first reported a position in VYNE Therapeutics in Q1 2020 and held it in 3 quarters.
  • Grace Capital's VYNE Therapeutics position peaked at $62K in Q2 2020.
  • 89 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q1 2021.

Based on Grace Capital's 13F filing for Q1 2021, filed 6 May 2021.